Alimta treatment for malignant pleural mesothelioma
The company’s Alimta treatment for malignant pleural mesothelioma saw sales of $73.1 million, up from $40 million in the third quarter, while sales of depression treatment Cymbalta were $61.3 million, compared with $32.5 million in the third quarter, mainly due to initial wholesaler stocking. Fourth-quarter sales of Forteo, a treatment for severe osteoporosis, were $74.3 million, up from $58.1 million in the third quarter.
(more…)